Two complementary studies in Nature Communications define a critical role for the anti-apoptotic protein MCL-1 as a driver of adaptive survival in tumor cells treated with oncogene targeted therapies, providing a rationale for combining these agents with newly developed MCL-1 inhibitors in the clinic.

中文翻译：

---

克服MCL-1驱动的针对靶向疗法的适应性耐药。

《自然通讯》中的两项补充研究确定了抗凋亡蛋白MCL-1作为用癌基因靶向疗法治疗的肿瘤细胞中适应性生存的驱动力的关键作用，为将这些药物与新开发的MCL-1抑制剂结合使用提供了理论依据。诊所。